Biomarker testing to predict treatment response and recurrence in liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects clinical data, imaging, pathology information, and available biospecimens from adults with HCC receiving standard therapies. It includes prospective and retrospective sample collection with residual tissue, slides, and blood when available, plus optional extra blood samples after consent. No new treatments are administered as part of the study; data and biospecimens are used for biomarker validation. The goal is to identify markers that correlate with treatment response and recurrence to improve prognosis and future care. Enrolled participants are followed through routine care at participating centers in Tianjin to accrue up to 500 individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Male or female aged ≥18 years. 2. HCC confirmed by imaging and/or pathology according to current Chinese guidelines.

  3\. Receiving standard antitumor therapy, such as surgery, ablation, TACE, targeted therapy, and/or immunotherapy, at participating centers and planned for systematic follow-up.

  4\. ECOG performance status 0-2; expected survival ≥3 months. 5. Child-Pugh class A or stable B; major organ function basically compensated. 6. Agrees to provide or authorize use of available clinical data, imaging/pathology information, residual tissue/wax blocks/slides from routine care, and/or residual blood samples. If additional peripheral blood collection is required, the purpose, volume, risks, sample use, and compensation arrangements will be specified in the informed consent form, and the participant must sign a separate written informed consent.

Exclusion Criteria:

* 1\. Active malignancy at other sites, or history of other malignancy within 5 years, except cured in situ carcinoma and basal cell skin carcinoma.

  2\. Prior liver transplantation or known immunodeficiency disease. 3. Severe heart, lung, renal, or other major organ dysfunction, or uncontrolled severe infection, unable to tolerate routine antitumor therapy and follow-up.

  4\. Decompensated liver function, such as obvious refractory ascites or hepatic encephalopathy, or Child-Pugh class C.

  5\. Pregnant or breastfeeding women, or women planning pregnancy who refuse effective contraception.

  6\. Severe mental disorders or extremely poor compliance, unable to complete follow-up and specimen collection.

  7\. Other conditions considered unsuitable for inclusion by the investigator.

Where it's running

• Tianjin Cancer Hospital
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Yang Liu, PhD.
• Email: yang_liu@tmu.edu.cn
• Phone: 02223340123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

  This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07838415

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

• DNP-MRSI to predict HCC treatment response

  This study tests whether DNP-MRSI imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism in liver tumors can indicate which BCLC A–C HCC lesions will respond after locoregional therapies or systemic treatment.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07807475

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.